Vancouver, British Columbia--(Newsfile Corp. - January 9, 2018) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical") is pleased to announce IRB approval of clinical trials for its "Carotid Stenotic Scan (CSS)" device at Michigan's prestigious Henry Ford Hospital. The trials will be overseen by Judith Lin, MD, MBA, RVT, RPVI, Senior Staff Vascular Surgeon and Medical Director of Henry Ford's Clinical Vascular Laboratory.
The Henry Ford Health System, founded in 1915, is one of the nation's leading providers of health care and boast a team of over 1,200 physicians. Their flagship hospital in the heart of Detroit is recognized for excellence in cardiology, cardiovascular surgery, and a broad spectrum of clinical specialties. The Clinical Vascular Laboratories at Henry Ford performs over 15,000 noninvasive testing annually in their state-of-the-art vascular laboratories accredited by Intersocietal Accreditation Commission.
"A partnership with an industry leader, such as the Henry Ford Health System, further validates the CVR technology," states CVR Chief Operations Officer Tony Robinson. "Dr. Lin, and her team, will play a vital role in this final step through FDA submission and clearance. It is my strong belief that by putting the CSS in the hands of professionals of this caliber we will see the true potential our device has to change the world."
"CVR Medical's Carotid Stenotic Scan is an innovative screening tool for determining the presence of carotid stenosis. This revolutionary technology aims to provide a cost-effective solution by reducing the number of unnecessary imaging for screening patients with carotid blockage," said Dr. Lin.
For additional information on the organization, leadership, and current news please visit the company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Director
For further information contact:
Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.